Vaccine News and Research

Latest Vaccine News and Research

U.S. H1N1 cases decreasing, CDC says; HHS to review approach to health-threat preparedness

The number of H1N1 (swine flu) cases in the U.S. appears to be decreasing, the CDC said Tuesday, CQ HealthBeat reports. "Flu was widespread in 32 states by the end of the week of Nov. 21, a decrease from 43 states in the prior week and 46 states earlier this fall, according to the CDC," the news service writes. "

3 Dec 2009

Officials to review U.S. health-threat response systems

The Washington Post: "Citing the balky swine flu vaccination campaign and other shortcomings in the nation's medical defenses, a top Obama administration official has announced a major review of the government's efforts to develop new protections against pandemics, bioterrorism and other health threats."

2 Dec 2009

Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study

Novavax, Inc. today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries.

2 Dec 2009

International AIDS Vaccine Initiative calls for redoubled efforts in vaccine development

As we approach World AIDS Day, observed globally December 1, we are reminded that while progress has been made in expanding access to treatment and prevention and that progress has been made toward the development of new prevention tools, the world is still falling short of established targets for providing universal access to HIV and AIDS prevention, treatment and care by 2010. Nearly 5.5 million of the estimated 9.5 million people in need of antiretroviral therapy are still not receiving it.

2 Dec 2009

Protein marker may hold the key against pancreatic cancer

Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.

2 Dec 2009

Jiangsu Yanshen Biological Technology Stock suspends production of all products

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that its subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen") has suspended production of all its products in order to conduct an internal inspection and improve its quality control systems.

2 Dec 2009

Sinovac Biotech receives fourth purchase order for its H1N1 vaccine from Chinese government

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its fourth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan.

2 Dec 2009

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.

2 Dec 2009

Bioactive sponge to eliminate normally fatal tumors

InCytu Incorporated, a therapeutic device engineering company, announced the details of its Cellarium™ Cancer Vaccine program. Cellarium™ is a small bioactive sponge which regulates dendritic cells and T-cells to eliminate normally fatal tumors in a preclinical model of late stage melanoma. The details of such a promising new vaccine were published for the first time in Science’s Translational Medicine Journal.

2 Dec 2009

Controlling NTDs can improve reproductive health and rights of women in poor countries

Controlling neglected tropical diseases (NTDs) in developing countries would help improve the reproductive health and rights of girls and women in the poorest countries of Africa, Asia, Latin America, and the Caribbean, according to a new editorial published November 24 in the open-access journal PLoS Neglected Tropical Diseases.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

MUHC researchers identify first genetic resistance factor against TB infection

Why do some people who are exposed to tuberculosis not become infected or develop the disease? Dr. Erwin Schurr and his team at the Research Institute from the McGill University Health Centre (RI-MUHC), in collaboration with Dr. Alexandre Alcais, from the Institut national de la sant- et de la recherche m-dicale (INSERM) in Paris, has shed light on this question for the first time. Their

2 Dec 2009

Vermont Department of Health chooses Emergency Management Software from Upp Technology

Upp Technology announced the selection of their irms|EM Emergency Management Software by the Vermont Department of Health to provide statewide distribution of emergency supplies, including H1N1 antivirals, personal protection equipment (PPE) and other medical supplies and equipment whether from the CDC's Strategic National Stockpile (SNS) or other inventory reserves.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

With flu season in full swing and the threat of H1N1 looming, demand for vaccines is at an all-time high. Although those vaccines are expected to be effective, University of Missouri researchers have found further evidence that some over-the-counter drugs, such as aspirin and Tylenol, that inhibit certain enzymes could impact the effectiveness of vaccines.

1 Dec 2009

Swine flu cases appear to have peaked

The current wave of pandemic H1N1 appears to have peaked, with four weeks of declines in several key indicators, the Centers for Disease Control and Prevention said Monday. Despite the decrease, the outbreak is continuing to take a heavy toll of hospitalizations and deaths, especially among children.

1 Dec 2009

New form of pathogen becomes a healthcare challenge in Africa

Research shows how a new, more deadly strain of Salmonella emerged over an 18-month period. Becoming resistant to antibiotics, acquiring the ability to spread from person to person and losing genes along the way, the new strain has become a healthcare challenge in Africa, killing up to one in four patients.

1 Dec 2009

HTDS finalizes contract details with Indian pharmaceutical company

Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India.

1 Dec 2009

Members of priority groups to receive H1N1 vaccines from Department of Health

The Department of Health reminded Pennsylvanians they can begin making appointments today to be vaccinated against the H1N1 flu virus.

1 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Vaccine News and Research

Latest Vaccine News and Research

U.S. H1N1 cases decreasing, CDC says; HHS to review approach to health-threat preparedness

Officials to review U.S. health-threat response systems

Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study

International AIDS Vaccine Initiative calls for redoubled efforts in vaccine development

Protein marker may hold the key against pancreatic cancer

Jiangsu Yanshen Biological Technology Stock suspends production of all products

Sinovac Biotech receives fourth purchase order for its H1N1 vaccine from Chinese government

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

Bioactive sponge to eliminate normally fatal tumors

Controlling NTDs can improve reproductive health and rights of women in poor countries

New approach to identify molecules that prevent immune cells from attacking body

MUHC researchers identify first genetic resistance factor against TB infection

Vermont Department of Health chooses Emergency Management Software from Upp Technology

CRO to run CEL-SCI's upcoming Phase III clinical trial

Missouri scientists discover aspirin and Tylenol can inhibit vaccine efficacy

Swine flu cases appear to have peaked

New form of pathogen becomes a healthcare challenge in Africa

HTDS finalizes contract details with Indian pharmaceutical company

Members of priority groups to receive H1N1 vaccines from Department of Health

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in